Features

“I’m upset because no one has offered me a clinical trial. When I asked about a trial in clinic today, my nurse did not know what to say.”

—Nichole Jefferson

Among patients with hypertension, previous treatment with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARBs) does not increase the risk of severe or fatal COVID-19, concludes a study in The Journal of the American Medical Association.

Urate-lowering therapy does not reduce the risk of progression in patients with chronic kidney disease (CKD), reports The New England Journal of Medicine./kidneynews/12_8/23/graphic/23f1.jpg

/kidneynews/12_8/21/graphic/21f1.jpg

Patients receiving dialysis in predominantly black neighborhoods have higher rates of hospitalization, and Black and Hispanic women have higher rates of hypertension after preeclampsia, according to a pair of studies.

Pages